ASX:RCE

Business news, market intelligence, and global industry analysis.

The Latest

Representative image of a leukemia drug development and biopharma acquisition theme, illustrating why Merck’s $6.7bn Terns Pharmaceuticals deal and TERN-701 are drawing attention as the Keytruda patent cliff approaches.

Merck’s $6.7bn Terns Pharmaceuticals buy puts CML drug TERN-701 in play as Keytruda patent cliff nears

Representative image of an Infosys office building, reflecting the firm’s global push to scale Topaz as a full-stack generative AI transformation platform.

Why is Infosys buying Stratus now as insurance platform modernization enters an AI-heavy phase?

Volex (AIM: VLX) upgrades FY2026 revenue to at least $1.22bn as AI data centre demand doubles and board eyes Main Market move

Boliden AB (STO: BOL) warns Garpenberg seismic damage will cut 2026 output and hit Q1 EBITDA

Recce Pharmaceuticals stock rises as Phase 3 trial begins in Indonesia: Can RCE prove its anti-infective breakthrough?

Recce Pharmaceuticals (ASX:RCE) stock gained as it began a Phase 3 trial in Indonesia for diabetic foot infections. Explore what this means for investors and AMR.

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

September 25, 2025